Institute For Neurodegenerative Disorders

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 2001-01-01

Employees: 101

Market Cap: -

Website: http://www.indd.org

Clinical Trials

Evaluation of [123I] AV51 and SPECT as a Marker of Beta-amyloid Protein Deposition in Subjects With Alzheimer Disease in Comparison to Healthy Subjects

Phase 1

Completed

Conditions: Alzheimer Disease

Interventions: Drug: [123I] AV-151

First Posted Date: 2007-11-12

Last Posted Date: 2019-03-14

Lead Sponsor: Institute for Neurodegenerative Disorders

Target Recruit Count: 20

Registration Number: NCT00556660

Locations: 🇺🇸
Molecular NeuroImaging, LLC, New Haven, Connecticut, United States
🇺🇸
Institute for Neurodegenerative Disorders, New Haven, Connecticut, United States

Evaluation of 123-I Iodobenzovesamicol (IBVM) and SPECT Imaging of Healthy Subjects and Patients With Alzheimer Disease

Phase 2

Completed

Conditions: Alzheimer Disease
Parkinson Disease

Interventions: Drug: [123I]-IBVM

First Posted Date: 2007-05-31

Last Posted Date: 2014-05-07

Lead Sponsor: Institute for Neurodegenerative Disorders

Target Recruit Count: 26

Registration Number: NCT00480701

Locations: 🇺🇸
Institute for Neurodegenerative Disorders, New Haven, Connecticut, United States

Assessment of the Effect of Sertaline on the Specific Binding of 123-I MZINT in Healthy Subjects

Phase 1

Terminated

Conditions: Depression

Interventions: Drug: 123-I MZINT injection and SPECT imaging

First Posted Date: 2007-05-08

Last Posted Date: 2019-04-03

Lead Sponsor: Institute for Neurodegenerative Disorders

Target Recruit Count: 30

Registration Number: NCT00470925

Locations: 🇺🇸
Institute for Neurodegenerative Disorders, New Haven, Connecticut, United States

Evaluation of [123I] MNI-187 and SPECT in Patients With Alzheimers Disease in Comparison to Healthy Subjects

Phase 1

Completed

Conditions: Alzheimers Disease

First Posted Date: 2007-04-05

Last Posted Date: 2019-03-14

Lead Sponsor: Institute for Neurodegenerative Disorders

Target Recruit Count: 30

Registration Number: NCT00456417

Locations: 🇺🇸
Institute for Neurodegenerative Disorders, New Haven, Connecticut, United States

Assessment of the Biodistribution and Safety of 123-I MZINT in Healthy Subjects and Parkinson Disease Patients

Phase 1

Terminated

Conditions: Parkinson Disease

Interventions: Drug: [123I] mZINT injection and serial dynamic SPECT imaging

First Posted Date: 2007-01-29

Last Posted Date: 2010-10-06

Lead Sponsor: Institute for Neurodegenerative Disorders

Target Recruit Count: 28

Registration Number: NCT00427674

Locations: 🇺🇸
Institute for Neurodegenerative Disorders, New Haven, Connecticut, United States

Assessing Imaging as a Tool in Monitoring and Predicting the Progression of Parkinson Disease

Phase 2

Completed

Conditions: Parkinson Disease

Interventions: Drug: B-CIT and SPECT imaging

First Posted Date: 2006-11-27

Last Posted Date: 2022-07-05

Lead Sponsor: Institute for Neurodegenerative Disorders

Target Recruit Count: 396

Registration Number: NCT00404170

Locations: 🇺🇸
Institute for Neurodegenerative Disorders, New Haven, Connecticut, United States

Evaluation of 5-[123I]-A-85380 and SPECT Imaging in Individuals With Parkinsons Disease

Phase 2

Completed

Conditions: Parkinson Disease

Interventions: Drug: [123I] 5-IA

First Posted Date: 2006-11-09

Last Posted Date: 2014-05-07

Lead Sponsor: Institute for Neurodegenerative Disorders

Target Recruit Count: 9

Registration Number: NCT00397696

Locations: 🇺🇸
Institute for Neurodegenerative Disorders, New Haven, Connecticut, United States

A Study Evaluating Potential Screening Tools for Detecting Parkinson Disease

Phase 2

Conditions: Parkinson Disease

Interventions: Procedure: [123I]β-CIT and SPECT imaging
Drug: [123I]β-CIT

First Posted Date: 2006-10-12

Last Posted Date: 2022-03-29

Lead Sponsor: Institute for Neurodegenerative Disorders

Target Recruit Count: 3000

Registration Number: NCT00387075

Locations: 🇺🇸
Institute for Neurodegenerative Disorders, New Haven, Connecticut, United States

The Study of the Impact of Disclosing Imaging Study Information to Trial Participants

Completed

Conditions: Parkinson
Parkinsonian Syndrome

First Posted Date: 2006-07-19

Last Posted Date: 2019-04-03

Lead Sponsor: Institute for Neurodegenerative Disorders

Target Recruit Count: 800

Registration Number: NCT00354003

Locations: 🇺🇸
Institute for Neurodegenerative Disorders, New Haven, Connecticut, United States

Biodistribution and Safety of a Radiopharmaceutical in Healthy Subjects

Phase 1

Completed

Conditions: Neurodegenerative Diseases

Interventions: Drug: 123-I INER

First Posted Date: 2006-04-21

Last Posted Date: 2014-04-10

Lead Sponsor: Institute for Neurodegenerative Disorders

Target Recruit Count: 35

Registration Number: NCT00316797

Locations: 🇺🇸
Institute for Neurodegenerative Disorders, New Haven, Connecticut, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy